RATINGS CHANGES

Abbott Labs (ABT - Get Report) was upgraded to buy from hold at Jefferies. $55 price target. Growth platforms are likely to remain strong in emerging markets, Jefferies said. 

Big Lots (BIG - Get Report) was downgraded to neutral from overweight at Piper Jaffray. $43 price target. Analysts have less confidence that management can achieve its aggressive guidance, Piper said.

Bluebird Bio (BLUE - Get Report) was downgraded to neutral from buy at Bank of America/Merrill Lynch. $102 price target. The company posted mixed data on sickle cell patients, analysts said.

Cowen (COWN - Get Report) was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: COWN.

Jarden (JAH) was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: JAH.

KBR (KBR - Get Report) was downgraded to sell from neutral at Goldman Sachs. $19 price target. The company is facing a challenging environment for LNG awards, Goldman said.

Eli Lilly (LLY - Get Report) was upgraded to buy at Deutsche Bank. $85 price target. Expect higher peak sales for the Alzheimer treatment, solanezumab, Deutsche Bank said.

Match Group (MTCH - Get Report) was initiated with an outperform rating at Wells Fargo. The demographic trends support broadening category usage, Wells said.

Norfolk Southern (NSC - Get Report) was upgraded to equal-weight from underweight at Barclays. The company can likely improve margins, Barclays said.

Sonoco Products (SON - Get Report) was downgraded to underweight at Barclays. $38 price target. The company is facing near-term challenges, Barclays said.

This article was written by a staff member of TheStreet.